跳至主要内容
临床试验/NCT01293422
NCT01293422已完成4 期

PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon

University of Oulu1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Glucose levels during oral glucose tolerance test

研究概览

简要总结

This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteer
  • Age 18-45 years
  • Body mass index 19-28

排除标准

  • Any continuous medication
  • Any significant disease
  • Allergy to rifampicin
  • Pregnancy and breast feeding
  • Fear of needles and previous difficult blood samplings
  • Substance abuse
  • Participation in another clinical drug trial within 1 month of enrollment
  • Use of soft contact lenses

研究组 & 干预措施

Rifampicin

Experimental

干预措施: Rifampicin (Drug)

结局指标

主要结局

Glucose levels during oral glucose tolerance test

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验